ArticleCurrent opinion in biomedical engineering2022
Tissue density in the progression of breast cancer: Bedside to bench and back again.
Article in Current opinion in biomedical engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets.Nature communications · 2026Article
- Developing virtual physiology of human tumor tissue for malignancy assessment.NPJ precision oncology · 2026Article
- Mammographic Breast Density at Breast Cancer Diagnosis and Breast Cancer-Specific Survival.Diagnostics (Basel, Switzerland) · 2024Article
- Multidimensional Imaging of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2023Review
- Protein disulfide isomerase A3 activity promotes extracellular accumulation of proteins relevant to basal breast cancer outcomes in human MDA-MB-A231 breast cancer cells.American journal of physiology. Cell physiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Women with high breast density are at notably greater risk for breast cancer. Moreover, breast tumor tissue can be up to 10-fold stiffer than normal tissue, containing dense extracellular matrix (ECM) proteins. This density affects numerous aspects of breast cancer progression, and as such is critical to patient diagnosis and treatment. Here, we review recent advances in using engineered models to understand the ramifications of dense breast tissue for tumor progression. Matrix density has been found to influence immune cell infiltration and stromal components of the tumor microenvironment, including fibroblast activation and tumor angiogenesis. Use of engineered scaffolds has also revealed that changing tissue density alters breast cancer metabolism. Going forward, the complexity and specificity of tissue-engineered scaffolds that more closely mimic the physiological breast microenvironment will continue to be developed, potentially even tailored to individual patients. A challenge going forward is the leveraging of these novel tools and knowledge gained about breast density to identify therapeutic targets to treat breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.